Integrated delivery systems and biologics drive the transition
- Stevanato sells glass drug containers, injectable drug delivery systems, and the equipment used to make them.
- High-value solutions, meaning premium syringes, cartridges, and ready-to-use products, reached 45% of revenue in Q2 2026.
- GLP-1 drugs were about 22% to 23% of total revenue in Q2 2026, giving the company a direct link to a fast drug category.
- The European regulatory approval of the proprietary Alina pen platform marks a major commercial milestone for integrated delivery systems.
- The BDS segment grew 9% in Q2 2026, while the struggling Engineering segment stabilized with only a 2% decline.
- Finn's view is balanced because growth is real, but the price and execution risks leave less room for mistakes.
A GLP-1 supplier executing its transition
The bull case is simple. Stevanato sells the picks and tools that drug companies need for biologic medicines, including GLP-1 drugs, monoclonal antibodies, and other injected treatments. These drugs often need better containers and better delivery systems than older medicines. That moves customers toward high-value solutions, the company's premium syringes, cartridges, and ready-to-use products.
That shift is accelerating. High-value solutions reached 45% of total revenue in Q2 2026, and GLP-1 drugs contributed approximately 22% to 23%. European regulatory approval of a liraglutide-based therapy using Stevanato's proprietary Alina variable dose pen validates the transition toward integrated drug delivery systems.
The bear case centers on margins and execution. New plants in Fishers and Latina add cost before they are fully loaded with orders. Engineering, the segment that sells glass conversion, inspection, assembly, and packaging equipment, has been a profitability drag. However, Q2 2026 showed early signs of stabilization, with the segment declining only 2%.
For the next year, the story depends on three watch points. First, Fishers must launch customer validation for its first EZ-fill vial line. Second, Engineering must turn quotes into signed orders. Third, the company must scale commercial production of the Alina and Deora pen platforms. The setup remains attractive as long as growth turns into better earnings.
Paid when drug makers scale injections
Stevanato makes money by selling primary packaging, delivery systems, contract manufacturing, and equipment to pharma, biotech, and life sciences customers. Primary packaging means the container that directly touches the medicine, such as a vial, syringe, or cartridge.
The best economics come when customers buy high-value solutions. These include ready-to-use vials, high-value syringes, EZ-fill cartridges, and products made for sensitive biologic drugs. Customers pay more because these products can reduce contamination risk, support automated filling, and work better with injection devices.
The company is accelerating its shift toward complex, integrated drug delivery systems. Management recently divested the contract manufacturing subsidiary Balda C. Brewer to focus purely on end-to-end partnerships for sensitive biologics and GLP-1s. A drug company might buy glass containers and use Stevanato device manufacturing for the final assembled product.
Where the model breaks is utilization. A new plant has people, equipment, depreciation, and quality work before it reaches full output. Fishers and Latina are strategically useful, especially for US supply, but they weigh on margins until volume catches up.
Containers, devices, and the machines behind them
High-value syringes
These are premium pre-fillable syringes used for more sensitive drugs. The company continues to expand capacity for these to meet strong market demand.
EZ-fill cartridges
Cartridges are used in pen injectors and similar devices. Stevanato's EZ-fill cartridges are crucial for GLP-1 applications, and management is actively adding more cartridge capacity.
Vials
Vials are a core drug container product. Demand was hurt by industry destocking in 2024, but order intake has since shown steady signs of recovery.
Pen and auto-injector systems
These products help patients take injected drugs at home. The European approval of the proprietary Alina pen and the introduction of the Deora pen are major commercial milestones.
Contract manufacturing for devices
Stevanato can manufacture device components or assemblies for drug companies. The Fishers site is being built out for commercial device programs.
Engineering equipment
This segment sells equipment for glass conversion, inspection, assembly, and packaging. It has been a drag on profitability but showed stabilization in mid-2026.
Alba portfolio
Alba is a next-generation product family aimed at highly sensitive drug products. It supports the same biologics trend that is lifting premium syringes and cartridges.
BDS carries the company while Engineering stabilizes
The Biopharmaceutical and Diagnostic Solutions (BDS) segment represents the vast majority of revenue, growing 9% in Q2 2026. This makes the company heavily tied to BDS demand and the ramp of high-value drug containment products.
What could break the setup
Fishers and Latina stay underused
High impact · Medium oddsStevanato is spending heavily to add capacity in Fishers, Indiana and Latina, Italy. New plants can hurt margins until they run at higher volume. Both sites remain margin dilutive during their ramp phases, though they are slowly gaining operating leverage.
Engineering orders stall again
Medium impact · Medium oddsEngineering revenue showed early signs of stabilization in Q2 2026, declining only 2%. Management says the pipeline exists, but customers have historically taken longer to make capital spending decisions. If the turnaround stalls and backlog does not rebuild, the segment can return to dragging revenue and profit.
GLP-1 exposure turns from help to concentration
High impact · Medium oddsGLP-1 drugs were about 22% to 23% of total revenue in Q2 2026. That is a strong tailwind while demand rises, but it also makes Stevanato more exposed to delays, price pressure, or changes in customer launch plans in one major drug category.
Tariffs and currency keep hitting profit
Medium impact · Medium oddsManagement's 2025 guidance assumed a 10% tariff rate for goods shipped from the EU to the US, with about EUR 4.5 million of operating profit impact. Foreign exchange also remains a headwind, with expected full-year pressure raised to between $15 million and $16 million.
Vial recovery stalls
Medium impact · Medium oddsVials were hurt by industry destocking in 2024, when customers worked down excess inventory. Management later noted that order intake was improving, but the recovery needs to show up in steady shipments. A weak vial rebound would reduce one support for BDS growth.
In one breath
What does Stevanato Group do?
Stevanato makes glass containers, injection devices, and production equipment for drug companies. Its products are used for medicines such as biologics, GLP-1 drugs, and other injectable treatments.
Why do GLP-1 drugs matter for STVN?
GLP-1 drugs often need syringes, cartridges, pens, and other delivery parts. In Q2 2026, GLP-1 drugs were about 22% to 23% of Stevanato's total revenue, making demand in that category a major growth driver.
What is the main risk for Stevanato stock?
The biggest risk is execution. Stevanato needs its new capacity in Fishers and Latina to fill up, while also completing the turnaround of its Engineering segment.
Is Stevanato only a GLP-1 company?
No. GLP-1 drugs are important, but Stevanato also serves monoclonal antibodies, other biologics, diagnostics, and broader injectable drug markets. The key question is whether growth stays broad enough outside GLP-1.
